Search Results for: biotech

CRISPR baby moratorium grows likely with rising tide of support including from biotech

CRISPR-gene-edit-vs-mutation-1

Trying to make a CRISPR baby any time soon would be a really bad idea. How bad? Last December 3rd I penned a piece for STAT News arguing for a moratorium on the heritable use of CRISPR in humans. This potential future, radical application of “gene editing” is now often colloquially referred to as “CRISPR …

CRISPR baby moratorium grows likely with rising tide of support including from biotech Read More »

Stem cell good news on biotechs & cool new organoid paper

Pham-et-al.-2018

There’s some recent stem cell good news out there including new papers and biotech developments. The stem cell and regenerative medicine field is really diverse and runs the gamut from really worrying stuff to very exciting, legit developments. In this post, I’m going to focus on the encouraging recent developments. What do I see as …

Stem cell good news on biotechs & cool new organoid paper Read More »

Stem cell fake news driving biotech investors or vice versa…or what?

US-Stem-Cell-Google-Search-e1495552962354

Is there a proliferating stem cell fake news problem in the biotech world? More broadly, the SEC is cracking down on the mess that is fake biotech news, but what about fake news on stem cell biotechs more specifically? Already in the past year I’ve seen examples of possible stem cell fake news. Hyped press releases (PR) …

Stem cell fake news driving biotech investors or vice versa…or what? Read More »

What is your favorite stem cell/regen med biotech & why?

stem cell stocks

I’m putting together a list of stem cell and regenerative medicine biotech companies for a blog post, including both public and private. I’ve got a good list already, but want it to be fairly comprehensive. I’m also curious what readers think are the most promising ones and why. So weigh in with comments please or …

What is your favorite stem cell/regen med biotech & why? Read More »

Nature Biotechnology looking at NgAgo paper amidst reproducibility concerns

NgAgo-China-newspaper

When potentially game changing new technologies are reported such as NgAgo gene editing, both scientists and the public get excited, but especially if such new reports stem from a single paper it is wise to take a cautious approach for a while. The key question is whether the new findings will turn out to be …

Nature Biotechnology looking at NgAgo paper amidst reproducibility concerns Read More »

End of line for StemCells Inc., pioneering & controversial stem cell biotech

stemcellsinc-logo

A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for …

End of line for StemCells Inc., pioneering & controversial stem cell biotech Read More »

Can Stemcentrx thrive as a biotech killing cancer stem cells?

stemcentrx.2x519

A stem cell biotech in the news this week was one that had mostly flown under the radar previously with aim to zap cancer stem cells. Stemcentrx has a focus on killing cancer stem cells as a novel approach to treating cancer. Antonio Regalado had a nice article yesterday on the company. He reports that Stemcentrx has …

Can Stemcentrx thrive as a biotech killing cancer stem cells? Read More »

Tale of 7 stem cell biotech stock woes

Ocata

To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those …

Tale of 7 stem cell biotech stock woes Read More »

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc

Katarina-Le-Blanc

The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical …

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »